Skip to content

0

DRUG19 trials

Sponsors

Ferring Pharmaceuticals A/S, Dermapharm AG, Gcp-Service International West GmbH, Silence Therapeutics PLC, Universitair Medisch Centrum Groningen, Universitair Medisch Centrum Groningen

Conditions

Biliary AtresiaCOVID-19CancerCholangiocarcinomaChronic PainCrohn's diseaseGastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adultsHerpes Zoster

Phase 1

Phase 2

Intravenous Fish Oil based Lipid Emulsion to enhance recovery in High-Risk Cardiac Surgery Patients: a phase II multicenter trial
RecruitingCTIS2023-503490-38-00
Gcp-Service International West GmbHcritical illness, intensive care unit (ICU), surgery
Start: 2023-11-15Target: 378Updated: 2025-12-11
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patients (STRIDE)
CompletedCTIS2023-506837-31-00
Itb-Med ABNew onset type I diabetes
Start: 2023-01-27End: 2025-10-20Target: 113Updated: 2025-03-24
A Randomized, Double-blind, Placebo-controlled, Phase 2/3 Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Obeticholic Acid Compared to Placebo in Pediatric Subjects with Biliary Atresia, Post-hepatoportoenterostomy
CompletedCTIS2023-503926-37-00
Intercept Pharmaceuticals Inc.Biliary Atresia, Post-hepatoportoenterostomy
End: 2025-09-17Target: 50Updated: 2025-10-03
(ASK-PD5-CS201) A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults with Moderate Stage Parkinson’s Disease
RecruitingCTIS2023-506519-16-00
Askbio Inc.Parkinson’s Disease
Start: 2025-04-11Target: 55Updated: 2026-01-27
"Imaging with 68Ga-DOTA-peptides and peptide receptor radionuclide therapy with 177Lu-DOTA-peptides of gastroenteropancreatic neuroendocrine tumors: interest of intra-arterial hepatic infusion in patients with dominant liver metastases" "LUTARTERIAL"
RecruitingCTIS2024-514785-39-00
Centre Hospitalier Universitaire De BordeauxGastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults
Start: 2021-09-24Target: 23Updated: 2024-11-04
Beta-blockade with landiolol in out-of-hospital cardiac arrest: a randomized, double-blind, placebo-controlled, pilot trial
RecruitingCTIS2024-518949-14-00
Medical University Of Viennacardiac arrest, ventricular fibrillation
Start: 2020-11-30Target: 48Updated: 2024-12-10
"Diagnostic value of 68Ga-FAPI-46 PET/CT in the initial work-up of pancreatic and biliary cancers eligible to a curative treatment" "FAPDIG"
Not yet recruitingCTIS2024-517270-23-00
Centre Hospitalier Universitaire De BordeauxCholangiocarcinoma, Pancreatic adenocarcinoma
Target: 120Updated: 2025-07-30

Phase 3

A randomised, controlled, assessor-blind, parallel groups, multicentre, multinational trial comparing the ovarian response after controlled ovarian stimulation with mixed protocols of follitropin delta (REKOVELLE) and highly purified human menopausal gonadotropin (MENOPUR) in women undergoing an assisted reproductive technology programme
Not yet recruitingCTIS2022-500308-23-00
Ferring Pharmaceuticals A/SInfertility in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle
Target: 115Updated: 2022-11-09
Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients
CompletedCTIS2023-503894-39-00
Universitair Medisch Centrum Groningen, Universitair Medisch Centrum GroningenCOVID-19, Herpes Zoster, impaired immunity +1
Start: 2023-08-22End: 2024-02-27Target: 110Updated: 2023-10-10
Brain Injury and Ketamine: a prospective, randomized controlled double blind clinical trial to study the effects of ketamine on therapy intensity level and intracranial pressure in acute brain injury patients.
RecruitingCTIS2023-505319-19-00
UZ LeuvenTraumatic brain injury
Start: 2021-09-01Target: 100Updated: 2024-02-21
Double-blind, randomised clinical study comparing efficacy and safety of Mecloderm® Ointment (Test) vs. Lotricomb® Ointment (Reference) vs. Vehicle in patients with moderate to severely inflamed candidiasis of the skin
RecruitingCTIS2022-501415-14-00
Dermapharm AGmoderate to severely inflamed candidiasis of the skin
Start: 2022-03-08Target: 552Updated: 2025-08-14
Screening for occult malignancy using 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in patients with unprovoked venous thromboembolism
Active, not recruitingCTIS2024-514703-34-00
Centre Hospitalier Regional Et Universitaire De BrestCancer, Thromboembolic event
Start: 2020-09-08Target: 638Updated: 2024-06-18
A Double-blind, Placebo-Controlled, Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
CompletedCTIS2024-514698-23-00
Sarepta Therapeutics Inc.Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.
Start: 2017-05-15End: 2025-10-09Target: 81Updated: 2025-06-19
(WHAT!) – RCT: Open-label randomized controlled trial for the effects of continuous daily use of ethinylestradiol/levonorgestrel (30/150 µg/day) compared with vitamin E (400 IU/day) in the treatment of menstrually-related migraine and perimenopausal migraine
Not yet recruitingCTIS2024-517127-40-00
Leids Universitair Medisch Centrum (LUMC)Migraine
Target: 360Updated: 2024-11-29
Evaluation of the efficacy of topical treatment with budesonide in children with Crohn's disease located in the esophagus and/or stomach and/or duodenum - BETHESDa
RecruitingCTIS2024-519269-23-00
Medical University Of WarsawCrohn's disease
Start: 2024-03-27Target: 138Updated: 2025-07-10

Phase 4

Unknown Phase